The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease
HMGCoA-inhibitors (statins) lower plasma cholesterol through interference with the rate-limiting enzyme in the endogenous synthesis process. Since their introduction in the early 90’s, the clinical attitude towards cardiovascular (cv) risk reduction has evolved from the attention to single risk fact...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd Medical Publishers
2006-09-01
|
| Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/261 |
| _version_ | 1818324210889523200 |
|---|---|
| author | Lorenzo Pradelli Orietta Zaniolo |
| author_facet | Lorenzo Pradelli Orietta Zaniolo |
| author_sort | Lorenzo Pradelli |
| collection | DOAJ |
| description | HMGCoA-inhibitors (statins) lower plasma cholesterol through interference with the rate-limiting enzyme in the endogenous synthesis process. Since their introduction in the early 90’s, the clinical attitude towards cardiovascular (cv) risk reduction has evolved from the attention to single risk factors to a more comprehensive global risk evaluation, and thus the indications of statins have broadened from the secondary prevention in hypercholesterolemic patients to include primary prevention in mildly and moderately hypercholesterolemic, or even normocholesterolemic patients, provided their global cv risk is considered high (typically, an estimated major cv event probability greater than 20%). Italian drug utilization data show that a small proportion of patients who could benefit from statins do actually receive them, contributing to the persistence of the clinical and economical burden of cv disease, the leading cause of mortality; since statins have proved effective, and cost-effective, in cv prevention, a more widespread use appears desirable, but requires high investments in pharmaceutical costs. This article defines a clinical profile of lovastatin, a statin with a solid efficacy and safety record only recently introduced into the Italian market despite it has been the first to become clinically available abroad. Among available statin formulations appropriate for target cholesterol reductions up to 30%, which apply to a significant proportion of statin therapy candidates, lovastatin 20 mg is marketed at the lowest price. Although the individual response to the different statins is highly unpredictable, determining a mandatory empirical molecule- and dose-finding strategy on the single patient, from the societal point of view the choice to start with lower cost molecules, among options that on average are equally-effective, may limit initial drug investment and dampen the impact of resource waste secondary to treatment interruptions and switches. |
| first_indexed | 2024-12-13T11:24:58Z |
| format | Article |
| id | doaj.art-82e120e5cdea4fe4a76c3166be9b0ff6 |
| institution | Directory Open Access Journal |
| issn | 2240-256X |
| language | English |
| last_indexed | 2024-12-13T11:24:58Z |
| publishDate | 2006-09-01 |
| publisher | SEEd Medical Publishers |
| record_format | Article |
| series | Farmeconomia: Health Economics and Therapeutic Pathways |
| spelling | doaj.art-82e120e5cdea4fe4a76c3166be9b0ff62022-12-21T23:48:16ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2006-09-017314115410.7175/fe.v7i3.261236The clinical and economic value of lovastatin in the primary prevention of cardiovascular diseaseLorenzo Pradelli0Orietta Zaniolo1Centro di ricerche Farmacoeconomiche, Advanced Research srlCentro di ricerche Farmacoeconomiche, Advanced Research srlHMGCoA-inhibitors (statins) lower plasma cholesterol through interference with the rate-limiting enzyme in the endogenous synthesis process. Since their introduction in the early 90’s, the clinical attitude towards cardiovascular (cv) risk reduction has evolved from the attention to single risk factors to a more comprehensive global risk evaluation, and thus the indications of statins have broadened from the secondary prevention in hypercholesterolemic patients to include primary prevention in mildly and moderately hypercholesterolemic, or even normocholesterolemic patients, provided their global cv risk is considered high (typically, an estimated major cv event probability greater than 20%). Italian drug utilization data show that a small proportion of patients who could benefit from statins do actually receive them, contributing to the persistence of the clinical and economical burden of cv disease, the leading cause of mortality; since statins have proved effective, and cost-effective, in cv prevention, a more widespread use appears desirable, but requires high investments in pharmaceutical costs. This article defines a clinical profile of lovastatin, a statin with a solid efficacy and safety record only recently introduced into the Italian market despite it has been the first to become clinically available abroad. Among available statin formulations appropriate for target cholesterol reductions up to 30%, which apply to a significant proportion of statin therapy candidates, lovastatin 20 mg is marketed at the lowest price. Although the individual response to the different statins is highly unpredictable, determining a mandatory empirical molecule- and dose-finding strategy on the single patient, from the societal point of view the choice to start with lower cost molecules, among options that on average are equally-effective, may limit initial drug investment and dampen the impact of resource waste secondary to treatment interruptions and switches.https://journals.seedmedicalpublishers.com/index.php/FE/article/view/261hmgcoa-inhibitorsstatinslovastatinprimary preventioncost-efficacy |
| spellingShingle | Lorenzo Pradelli Orietta Zaniolo The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease Farmeconomia: Health Economics and Therapeutic Pathways hmgcoa-inhibitors statins lovastatin primary prevention cost-efficacy |
| title | The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease |
| title_full | The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease |
| title_fullStr | The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease |
| title_full_unstemmed | The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease |
| title_short | The clinical and economic value of lovastatin in the primary prevention of cardiovascular disease |
| title_sort | clinical and economic value of lovastatin in the primary prevention of cardiovascular disease |
| topic | hmgcoa-inhibitors statins lovastatin primary prevention cost-efficacy |
| url | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/261 |
| work_keys_str_mv | AT lorenzopradelli theclinicalandeconomicvalueoflovastatinintheprimarypreventionofcardiovasculardisease AT oriettazaniolo theclinicalandeconomicvalueoflovastatinintheprimarypreventionofcardiovasculardisease AT lorenzopradelli clinicalandeconomicvalueoflovastatinintheprimarypreventionofcardiovasculardisease AT oriettazaniolo clinicalandeconomicvalueoflovastatinintheprimarypreventionofcardiovasculardisease |